HUTCHMED (00013) announced that following the renewal of the national medical insurance agreement with China's National Healthcare Security Administration (NHSA), ELUNATE®, ORPATHYS®, and SULANDA® will continue to be included in the updated National Reimbursement Drug List (NRDL), effective from January 1, 2026. Additionally, TAZVERIK® has been included in the first edition of the National Commercial Health Insurance Innovative Drug List.